Ozempic and Kidney Disease: What the FLOW Trial Means for You
- Sean Hashmi, MD
- May 27
- 8 min read
This is for anyone with type 2 diabetes whose kidney numbers have been drifting the wrong way, who has been told there is nothing more to do beyond an ACE inhibitor.
What We Have Been Fighting in Diabetic Kidney Disease
In diabetic kidney disease, the enemy is not the blood sugar number alone. It is the silent environment the kidneys have been bathing in for years. High blood sugars. High blood pressure. Low-grade inflammation that no patient can feel. Those environmental factors scar the filters inside the kidneys one nephron at a time. By the time creatinine moves on a lab report, a huge chunk of function is already gone.
For two decades in clinic, the conversation has gone the same way. Your kidney function is dropping. We can slow it, but we cannot stop it. Here is your ACE inhibitor. See you in three months.
That conversation is over.
The FLOW Trial: What Changed
The FLOW trial was a Phase 3 study of weekly semaglutide in adults with type 2 diabetes and chronic kidney disease. 3,533 people enrolled across 28 countries. Average follow-up of about 3.4 years.
The patients in the trial were already on standard care. That meant an ACE inhibitor or an ARB, often metformin, and sometimes an SGLT2 inhibitor like empagliflozin or dapagliflozin. These were patients already doing everything we had to offer, and still losing kidney function every year we checked.
The Primary Endpoint
The primary endpoint was a composite of major kidney events: a sustained 50 percent or greater drop in eGFR, progression to kidney failure (dialysis or transplant), death from kidney causes, or death from cardiovascular causes.
When the data monitoring committee looked at the interim numbers in late 2023, the benefit was so clear they recommended stopping the trial.
The Headline Results
Four endpoints. Four reductions. Each one large enough to change clinical practice on its own:
Composite kidney outcome: 24 percent reduction with semaglutide compared to placebo.
Albuminuria (protein in urine): 38 percent reduction.
Major adverse cardiovascular events: 18 percent reduction.
All-cause mortality: 20 percent reduction.
Read the last number again. Patients on semaglutide in this trial were 1 in 5 less likely to die from any cause over three and a half years. This is the first trial in clinical memory where the tool did not just slow the loss. It changed the trajectory.
How a Weight Loss Drug Saves Kidneys: Four Mechanisms
1. Glucose
Semaglutide lowers blood sugar in a glucose-dependent way. Less glycation. Less oxidative stress. Less damage to the small vessels feeding the kidney.
2. Weight
Patients lose roughly 10 to 15 percent of their body weight on higher doses. Less visceral fat means a smaller inflammatory load on every organ, including the kidneys.
3. Pressure
There is a modest blood pressure reduction, and the drug produces natriuresis, the kidney term for getting rid of extra salt in the urine. That translates to less force pushing on the inside of the kidney filter.
4. Inflammation
This is where the drug becomes a true kidney-saving therapy. If you have wondered why chasing the A1c with more insulin never seemed to protect your kidneys, this is the answer. Insulin lowers the sugar, but it does not touch inflammation. The scarring inside diabetic kidneys is driven by chronic low-grade inflammation that no glucose-lowering drug in the previous arsenal could touch.
GLP-1 receptors sit on immune cells, on the cells lining your blood vessels, and on cells inside the kidney itself. Activating them appears to dampen the slow burn that drives diabetic kidney scarring. In other words, you are not just lowering the heat from outside the pot. You are turning down the burner.
Why This Matters: The Benefit Is Additive
One piece of clinical context is worth holding on to. The benefit in the FLOW trial was stacked on top of ACE inhibitors, ARBs, and SGLT2 inhibitors. The effects were additive.
Kidney-protective therapies are no longer a choice between options. They are layered. ACE inhibitor or ARB plus SGLT2 inhibitor plus semaglutide is the new architecture for the right patient. That is a shift, and it matters.
Four Actionable Steps Before Your Next Appointment
Step 1: Pull Your Last Lab Panel
Before your next visit, pull up your most recent lab panel. Two numbers matter most: your kidney function (eGFR) and your urine albumin-to-creatinine ratio (UACR).
The FLOW trial enrolled adults with type 2 diabetes and an eGFR between 25 and 75, with elevated albumin in the urine. The conversation thresholds break down by eGFR:
eGFR 50 to 75: If your UACR is above 300 mg/g, the FLOW conversation applies to you.
eGFR 25 to 50: If your UACR is above 100 mg/g, the FLOW conversation applies to you.
If you do not have a UACR on file, that is the first thing to ask your doctor for. Primary care offices often skip it. If you have diabetes, the UACR should be checked at least annually.
Step 2: Bring the Trial Up at the Visit, Not at a Med Spa
Once you know your numbers, the next move is a conversation with your nephrologist, endocrinologist, or primary care physician. Not a compounded version from a website. A specific ask works better than a general one.
"I read about the FLOW trial in diabetic kidney disease. My eGFR is ___, and my urine albumin-to-creatinine ratio is ___. Am I a candidate for semaglutide for kidney protection?"
That sentence does three things. It puts you in the trial population. It names the indication (kidney protection, not weight loss). It signals you have done your homework.
The One Absolute Contraindication
If you or a first-degree relative has a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, this drug is not for you. That is a hard stop, not a soft warning.
Step 3: Build a Sick Day Plan at the Prescribing Visit
If you start semaglutide, the side effect that matters most for your kidneys is dehydration. Nausea, vomiting, diarrhea, and constipation are common, especially in the first few months. If you cannot keep fluids down for more than 24 hours while on this drug, you can spiral into acute kidney injury fast.
Three questions need to come out of that first prescribing visit. When do I hold the drug? When do I call the office? When do I go to the emergency room? Write the answers down. Put them in your phone. The plan exists before you need it, not during.
Step 4: Defend Your Muscle and Track the Right Numbers
Rapid weight loss on any drug costs you both fat and muscle. To skew the loss toward fat, two things have to be in place.
Resistance training two or three sessions per week. Bands, machines, body weight, dumbbells. The drug does not build muscle for you.
Adequate protein for your kidney stage. Plant-based protein is the most kidney-friendly option. The exact target depends on your eGFR and is the right question for your nephrologist or a renal dietitian. This is not the question to Google or freelance. Ask the specialist.
Once you start, the numbers to track are not your weight. They are your eGFR, your UACR, your blood pressure, and your A1c. Every three to six months, depending on your stage. Those are the signals that tell you the drug is doing the job it was actually approved for.
Why the SELF Framework Matters More, Not Less
This is the moment when the SELF framework (Sleep, Exercise, Love, Food) becomes more important, not less. Sleep matters because poor sleep blunts insulin sensitivity. Exercise matters because the drug does not build muscle for you. Love and connection matter because chronic stress drives the same inflammation the drug is fighting. And a whole food, plant-predominant diet matters because the kidneys still care what you put on the plate.
The drug is a tool. It works best bolted onto sleep, exercise, connection, and food. Not instead of them.
The Takeaway
If you have type 2 diabetes and chronic kidney disease, the FLOW data is the most important thing to have read before your next appointment. Bring it up. The answer might still be no for reasons that belong to you and your doctor, but the question has to be asked.
Frequently Asked Questions
Is Ozempic approved for kidney disease?
In 2025, the FDA expanded the approval of semaglutide (the active ingredient in Ozempic) to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. The approval was based on the FLOW trial.
What did the FLOW trial show?
The FLOW trial enrolled 3,533 adults with type 2 diabetes and chronic kidney disease. Patients on weekly semaglutide had a 24 percent reduction in major kidney events, a 38 percent reduction in albuminuria, an 18 percent reduction in major adverse cardiovascular events, and a 20 percent reduction in death from any cause over a median follow-up of 3.4 years.
Who qualifies for semaglutide for kidney protection?
The FLOW trial enrolled adults with type 2 diabetes, an eGFR between 25 and 75 mL/min/1.73m2, and elevated albumin in the urine. Specific UACR thresholds varied by eGFR range. Eligibility for treatment is a clinical decision made with your physician based on your full medical history.
Can I take semaglutide if I am already on an ACE inhibitor or SGLT2 inhibitor?
Yes, and the FLOW trial specifically tested semaglutide in patients already on standard kidney-protective therapy. The benefit was additive. Layering ACE inhibitors or ARBs with SGLT2 inhibitors and semaglutide is the new architecture for appropriate patients.
What is the main contraindication?
Personal or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is a hard contraindication to all GLP-1 receptor agonists, including semaglutide.
What is the biggest kidney risk while on semaglutide?
Dehydration from gastrointestinal side effects (nausea, vomiting, diarrhea). If you cannot keep fluids down for more than 24 hours, you risk acute kidney injury. Build a sick day plan with your prescribing physician at the first visit.
Do I still need to focus on diet and exercise on semaglutide?
Yes. The drug does not build muscle, manage your sleep, reduce your stress, or replace plant-predominant whole-food eating. Resistance training, adequate protein for your kidney stage, and the SELF framework remain essential. The drug is a tool, not a replacement.
References
• Perkovic V, Tuttle KR, Rossing P, et al. (2024). Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). New England Journal of Medicine, 391(2), 109-121. [VERIFY DOI against PubMed before publish]
• KDIGO (2024). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. https://kdigo.org/guidelines/ckd-evaluation-and-management/
• U.S. Food and Drug Administration (2025). Expanded indication for semaglutide (Ozempic) for reduction in risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD. [VERIFY FDA approval date and exact label language]
• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. (2020). Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD). New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
• American Diabetes Association (2024). Standards of Care in Diabetes: Chronic Kidney Disease and Risk Management. Diabetes Care, 47(Suppl 1).
Get the Free Kidney Guide
Drop your email and get the evidence-based guide Dr. Sean Hashmi uses to help patients understand their kidney numbers, advocate for the right tests, and protect kidney function. No spam, just useful.
Watch Next
A short walk-through of the urine albumin-to-creatinine ratio (UACR), the same test you need before bringing the FLOW trial conversation to your doctor. If you do not yet know your UACR number, start here.
This article is for educational purposes only and is not medical advice. Always consult your healthcare provider for individual care. The views expressed are Dr. Hashmi's own and do not represent his employer. Never start, stop, or change the dose of any prescription medication without consulting your physician.
Comments